Progressive @entity73 in combination with a cerebrospinal fluid biomarker pattern of low levels of amyloid-b1-42 and high levels of total tau and phosphorylated tau is typical of @entity195 . However, several @entity179 may overlap with @entity195 both in regards to clinical symptoms and neuropathology. In a uniquely large cohort of @entity303 @entity1 , we examined the associations of cerebrospinal fluid biomarkers for @entity195 molecular pathology with clinical @entity303 diagnoses and disease severity. We cross-referenced the Swedish @entity303 Registry with the clinical laboratory database at the Sahlgrenska University Hospital. The final data set consisted of 5676 unique subjects with a clinical @entity303 diagnosis and a complete set of measurements for cerebrospinal fluid amyloid-b1-42, total tau and phosphorylated tau. In cluster analysis, disregarding clinical diagnosis, the optimal natural separation of this data set was into two clusters, with the majority of @entity1 with early onset @entity195 (75%) and late onset @entity195 (73%) assigned to one cluster and the @entity1 with @entity1294 (91%), @entity4943 (94%), @entity191 (94%) and @entity303 with @entity1832 (87%) to the other cluster. @entity4943 had the highest cerebrospinal fluid levels of amyloid-b1-42 and the lowest levels of total tau and phosphorylated tau. The highest levels of total tau and phosphorylated tau and the lowest levels of amyloid-b1-42 and amyloid-b1-42:phosphorylated tau ratios were found in @entity195 . Low amyloid-b1-42, high total tau and high phosphorylated tau correlated with low Mini-Mental State Examination scores in @entity195 . In @entity191 and @entity1294 low cerebrospinal fluid amyloid-b1-42 was associated with low Mini-Mental State Examination score. In the @entity1294 , @entity4943 , @entity303 with @entity1832 and @entity191 groups 53%, 34%, 67% and 53% of the subjects, respectively had abnormal amyloid-b1-42 levels, 41%, 41%, 28% and 28% had abnormal total tau levels, and 29%, 28%, 25% and 19% had abnormal phosphorylated tau levels. Cerebrospinal fluid biomarkers were strongly associated with specific clinical @entity303 diagnoses with @entity195 and @entity4943 showing the greatest difference in biomarker levels. In addition, cerebrospinal fluid amyloid-b1-42, total tau, phosphorylated tau and the amyloid-b1-42:phosphorylated tau ratio all correlated with poor cognitive performance in @entity195 , as did cerebrospinal fluid amyloid-b1-42 in @entity191 and @entity1294 . The results support the use of cerebrospinal fluid biomarkers to differentiate between @entity303 in clinical practice, and to estimate disease severity.

Cerebrospinal fluid tau and amyloid-b1-42 in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity303 :: ('MESH:D003704', 'Disease') :: ['dementias', 'Dementia', 'dementia'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive decline'] @entity1294 :: ('MESH:D015140', 'Disease') :: ['vascular dementia'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease dementia"] @entity1832 :: ('MESH:D020961', 'Disease') :: ['Lewy bodies'] @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative disorders'] @entity195 :: ('MESH:D000544', 'Disease') :: ["Alzheimer's disease"] @entity4943 :: ('MESH:D057180', 'Disease') :: ['frontotemporal dementia', 'Frontotemporal dementia']
@entity303 :: (MESH:D003704,Disease) :: ['dementia']
